… Medical Campus, contextualized the use of tislelizumab as a frontline treatment … tumor site, grade, somatostatin receptor expression, and … 3 NIAGARA trial (NCT03732677) supported the FDA’s … and Harvard Medical School, detailed clinical trials investigating …

… described peptide-drug conjugates consisting of peptide targeting somatostatin receptors covalently bound … to be useful for the treatment of cancer. BioWorld Science Cancer …

… Trials Network. It was a randomized, double-blinded, placebo-controlled trial … therapy targeting the somatostatin receptor, molecularly … of treatment efficacy. References: 1. FDA approves … fda.gov/drugs/;resources-information-approved-drugs/fda …

… trials that evaluated paltusotine for the treatment of acromegaly in medically … Drug Administration (FDA) of the New Drug Application (NDA) for paltusotine for the treatment … Pharmaceuticals   Crinetics Pharmaceuticals is a clinical stage pharmaceutical …

The US Food and Drug Administration (FDA) has approved Exelixis’ Cabometyx (cabozantinib) … from the late-stage CABINET trial, which evaluated Cabometyx against … important new treatment option for patients, without limitations based on somatostatin receptor …

… associate professor of medicine at Harvard Medical School and clinical … the FDA approval of cabozantinib (Cabometyx) for the treatment of … the phase 3 CABINET trial (NCT03375320), which showed … well as those with somatostatin receptor–positive and –negative …

… -saving treatments. How bioconjugates transform treatment Alongside creating new treatments for … that have advanced drug development across the pharmaceutical industry. Its … investigational medicinal product (IMP) or drug substance for first clinical trials …

… FDA announced the approval of cabozantinib for the treatment … of Medicine. The multicenter, double-blind phase 3 trial … according to concurrent somatostatin analogue use and … ;www.fda.gov/drugs/;resources-information-approved-drugs/fda-approves- …

… the phase 3 CABINET trial (NCT03375320), in which … England Journal of Medicine showed that treatment with cabozantinib … 1 prior therapy, excluding somatostatin analogs, in both … and Drug Administration (FDA) accepted the supplemental New Drug Application …

… Cabometyx; Exelixis) received FDA approval after demonstrating a … tumors (epNET).1 The drug is indicated to treat … trial results were presented at the 2024 European Society for Medical … treatment option for patients, without limitations based on somatostatin …